DiaMedica Therapeutics Inc (DMAC) — Titan Protect Analysis

DMAC

DiaMedica Therapeutics Inc

Healthcare · ·

$5.64

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$309M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.52

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-86.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.00

+130% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulin

https://www.diamedica.com

Country: United States Employees: 35 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.841

Good returns relative to risk taken

Kelly Fraction

0.0586

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.868

Acceptable balance between returns and drawdown risk

Annual Return

42.7%

Historical annualised return based on price data

Max Drawdown

-49.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.99

Less volatile than the market — more defensive

52W High

$10.42

46% below the year high

52W Low

$3.48

62% above the year low

Avg Volume

190,752

Average daily shares traded — higher means easier to buy and sell

Short Ratio

30.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.71

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.45

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-18,008,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-35,101,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$13.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go